397 related articles for article (PubMed ID: 31974807)
1. Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease.
Schneider SA; Alcalay RN
J Neurol; 2020 Mar; 267(3):860-869. PubMed ID: 31974807
[TBL] [Abstract][Full Text] [Related]
2. Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.
von Linstow CU; Gan-Or Z; Brundin P
Transl Neurodegener; 2020 Oct; 9(1):39. PubMed ID: 33066808
[TBL] [Abstract][Full Text] [Related]
3. New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin.
Senkevich K; Rudakou U; Gan-Or Z
Neuropharmacology; 2022 Jan; 202():108822. PubMed ID: 34626666
[TBL] [Abstract][Full Text] [Related]
4. Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism.
Schneider SA; Hizli B; Alcalay RN
Neurotherapeutics; 2020 Oct; 17(4):1378-1392. PubMed ID: 32914362
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
[TBL] [Abstract][Full Text] [Related]
6. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
[TBL] [Abstract][Full Text] [Related]
7. A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease.
Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Mirelman A; Thaler A
Mov Disord; 2020 Jul; 35(7):1249-1253. PubMed ID: 32353202
[TBL] [Abstract][Full Text] [Related]
8. Autosomal dominant Parkinson's disease: Incidence of mutations in LRRK2, SNCA, VPS35 and GBA genes in Brazil.
Abreu GM; Valença DC; Campos M; da Silva CP; Pereira JS; Araujo Leite MA; Rosso AL; Nicaretta DH; Vasconcellos LF; da Silva DJ; Della Coletta MV; Dos Santos JM; Gonçalves AP; Santos-Rebouças CB; Pimentel MM
Neurosci Lett; 2016 Dec; 635():67-70. PubMed ID: 27777137
[TBL] [Abstract][Full Text] [Related]
9. Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease.
da Silva CP; de M Abreu G; Cabello Acero PH; Campos M; Pereira JS; de A Ramos SR; Nascimento CM; Voigt DD; Rosso AL; Araujo Leite MA; Vasconcellos LFR; Nicaretta DH; Della Coletta MV; da Silva DJ; Gonçalves AP; Dos Santos JM; Calassara V; Valença DCT; de M Martins CJ; Santos-Rebouças CB; Pimentel MMG
J Neurol Sci; 2017 Oct; 381():160-164. PubMed ID: 28991672
[TBL] [Abstract][Full Text] [Related]
10. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
[TBL] [Abstract][Full Text] [Related]
11. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
12. Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes.
Thaler A; Kozlovski T; Gurevich T; Bar-Shira A; Gana-Weisz M; Orr-Urtreger A; Giladi N; Mirelman A
Mov Disord; 2018 Oct; 33(10):1656-1660. PubMed ID: 30288804
[TBL] [Abstract][Full Text] [Related]
13. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
[TBL] [Abstract][Full Text] [Related]
14. Variants in PSMB9 and FGR differentially affect Parkinson's disease risk in GBA and LRRK2 mutation carriers.
Shani S; Goldstein O; Gana-Weisz M; Bar-Shira A; Thaler A; Gurevich T; Mirelman A; Giladi N; Alcalay RN; Orr-Urtreger A
Parkinsonism Relat Disord; 2023 Jun; 111():105398. PubMed ID: 37116292
[TBL] [Abstract][Full Text] [Related]
15. Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.
Thaler A; Kliper E; Maidan I; Herman T; Rosenberg-Katz K; Bregman N; Gurevich T; Shiner T; Hausdorff JM; Orr-Urtreger A; Giladi N; Mirelman A
Brain Topogr; 2018 Nov; 31(6):1029-1036. PubMed ID: 29846835
[TBL] [Abstract][Full Text] [Related]
16. The genetic background of Parkinson's disease and novel therapeutic targets.
Salamon A; Zádori D; Szpisjak L; Klivényi P; Vécsei L
Expert Opin Ther Targets; 2022 Oct; 26(10):827-836. PubMed ID: 36524726
[TBL] [Abstract][Full Text] [Related]
17. Occupational Pesticide Exposure in Parkinson's Disease Related to GBA and LRRK2 Variants.
Brown EG; Goldman SM; Coffey CS; Siderowf A; Simuni T; Meng C; Brumm MC; Caspell-Garcia C; Marek K; Tanner CM;
J Parkinsons Dis; 2024; 14(4):737-746. PubMed ID: 38820021
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of pre-diagnostic symptoms did not differ between LRRK2-related, GBA-related and idiopathic patients with Parkinson's disease.
Liu SY; Zheng Z; Gu ZQ; Wang CD; Tang BS; Xu YM; Ma JH; Zhou YT; Feng T; Chen SD; Chan P;
Parkinsonism Relat Disord; 2018 Dec; 57():72-76. PubMed ID: 30119933
[TBL] [Abstract][Full Text] [Related]
19. Left corticospinal tract could be a biomarker to identify the dual prodromal LRRK2/GBA mutated Parkinson's disease.
Lin F; Ruan X; Zou X; Weng H; Zeng Y; Zheng J; Ye Q; Meng F; Chen X; Cai G
CNS Neurosci Ther; 2024 Jun; 30(6):e14728. PubMed ID: 38837664
[TBL] [Abstract][Full Text] [Related]
20. LRRK2, GBA and SMPD1 Founder Mutations and Parkinson's Disease in Ashkenazi Jews.
Dagan E; Schlesinger I; Kurolap A; Ayoub M; Nassar M; Peretz-Aharon J; Gershoni-Baruch R
Dement Geriatr Cogn Disord; 2016; 42(1-2):1-6. PubMed ID: 27449028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
